Eli Lilly’s Triple-G Drug Retatrutide Hits 22.6% Weight Loss But Fails To Prove Cardio Risk Reduction
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug reduces cardiovascular risk.
On analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.
Eli Lilly
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“On analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.”
stat news — STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit“Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug reduces cardiovascular risk.”
fierce biotech — <a href="/biotech/lillys-triple-g-drug-hits-226-weight-loss-cardio-risk-impact-disappoints" hreflang="en">Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear</a>